News Briefing channel feed

Mod­er­na ex­pands pipeline to in­clude liv­er dis­ease pro­grams; Im­pe­r­i­al re­searchers team up with Hep­tares on gas­troin­testi­nal dis­eases

8 years ago

Glob­al Blood Ther­a­peu­tic­s' sick­le cell dis­ease drug gets break­through ther­a­py sta­tus; Boehringer In­gel­heim will man­u­fac­ture BeiGene's PD-1 in­hibitor in Shang­hai

8 years ago

Shire cre­ates sep­a­rate neu­ro­sciences di­vi­sion for fu­ture in­vest­ments; Agenus gains $28M in roy­al­ty deal

8 years ago

Lund­beck part­ners with Van­der­bilt on new schiz­o­phre­nia drug; Pere­grine of­fi­cial­ly re­named Avid BioSer­vices in pur­suit of CD­MO iden­ti­ty

8 years ago

Biotech in­vestapalooza con­tin­ues with more ven­ture rounds for star­tups; Ova­Science cuts half of its work­force (again)

8 years ago

Cel­gene and blue­bird make a 'break­through' on BC­MA-tar­get­ing CAR-T; An­oth­er can­cer drug biotech gar­ners $39M start­up round for I/O work

8 years ago

Mi­crosoft, Google back DNAnexus' Big Da­ta work with $58M; No­var­tis, Temasek back $50M round for Pear’s med apps

8 years ago

No­var­tis' Tafin­lar/Mekin­ist com­bo for melanoma gets pri­or­i­ty re­view des­ig­na­tion; Fo­s­un Phar­ma backs joint ven­ture's $190M share is­sue

8 years ago

Tra­con inks deal with Am­brx to de­vel­op can­cer drug in Chi­na; Roche wins con­sec­u­tive ap­provals in EU and US

8 years ago

Bris­tol-My­ers takes a stake in Taris Bio­med­ical; Zai Lab, Five Prime strike a deal to de­vel­op tu­mor im­munother­a­py in Chi­na

8 years ago

Roche strikes an €87.5M dis­cov­ery deal with Con­fo; On­cono­va out-li­cens­es pre­clin­i­cal drug to Chi­na's HanX

8 years ago

Apo­tex founder and wife's death now sus­pect­ed homi­cide; Spec­trum CEO Ra­jesh Shrotriya fired

8 years ago

Cel­gene forges can­cer pact with CRT; FDA OKs Pfiz­er's Xel­janz as treat­ment for pso­ri­at­ic arthri­tis

8 years ago

Pfiz­er's Ix­i­fi gets ap­proved as third Rem­i­cade biosim­i­lar; No­vo Nordisk li­cens­es re­MYN­D's di­a­betes pro­gram in po­ten­tial €350M deal

8 years ago

Eli Lil­ly high­lights key R&D cat­a­lysts for 2018; Ver­nalis and Dai­ichi Sankyo work to­geth­er on can­cer tar­gets

8 years ago

Medi­gene, RXi strike re­search deal to im­prove TCRs; Bris­tol-My­ers pays PsiOxus $15M mile­stone for tri­al-ready on­colyt­ic virus

8 years ago

Hookipa rais­es $60M to fund im­munother­a­py R&D; Roche bags Io­n­is op­tion for $45M; Re­gen­eron fights back against No­var­tis' Eylea ri­val

8 years ago

Ery­tech shares crater as PhI­Ib AML study flops; Syn­log­ic, Gingko col­lab­o­rate on dis­cov­ery work; Ac­tive Biotech forced to sell prop­er­ty due to Teva's drug fail­ure

8 years ago

Canada's AmorChem launch­es $44.2M life sci­ence fund; Neon adds $36M, Mer­ck part­ner­ship in neoanti­gen dri­ve; CRISPR Ther­a­peu­tics files a CTA

8 years ago

Athyri­um rais­es $2B for debt/eq­ui­ty fund; Am­gen teams with Car­mot on Parkin­son's; Neu­ral­stem soars on failed study(?)

8 years ago

Cel­lec­tis re­cruits ex-Servi­er re­search chief De­pil; Are­na inks $224M deal on new drugs; JLABS heads to Shang­hai; As­traZeneca vet takes Goldfinch helm

8 years ago

Ven­ter quick­ly grabs the reins back at Hu­man Longevi­ty; Pe­ter Thiel backs up­start ChemomAb

8 years ago

Ac­tive Biotech shares crater af­ter Teva's MS drug laquin­i­mod flops (again); FDA ap­proves Foun­da­tion Med­i­cine's ge­nom­ic tu­mor di­ag­nos­tic test

8 years ago

Sen­a­tors grill Alex Azar on drug prices; Mor­phoSys sells rights to Darza­lex ri­val in $120M deal; Se­r­i­al deal­mak­er X-Chem en­ters new dis­cov­ery pact with Gilead

8 years ago
First page Previous page 63646566676869 Next page Last page
A service from the Financial Times